5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca

ONCOLOGY

Volumn 11, Issue 9 SUPPL. 10, 1997, Pages 48-49

  Skillings, Jamey R ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; UFT;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; LEUCOVORIN; TEGAFUR; URACIL;

EID: 0030731884     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (2)

1. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of tegafur and uracil plus oral leucovorin. An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994.
2. Gonzalez-Baron M, Feliu J, de la Gandara I, et al: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31:2215-2219, 1995.